Drug intelligence / Profile preview

AJ-099(I)

Development stage: Unknown
Lead developer: A&J Science
Modality: Small Molecules
Administration: Inhalation

Overview

AJ-099(I) is an inhaled antimicrobial small molecule being developed by A&J Science for the treatment of refractory chronic lung infections. It exhibits broad-spectrum activity against several difficult-to-treat pathogens, including *Pseudomonas aeruginosa*, *Mycobacterium abscessus* (NTM-MAB), *Mycobacterium avium* complex (NTM-MAC), and multidrug-resistant *Mycobacterium tuberculosis* (MDR-TB). The drug is designed for direct delivery to the lungs via inhalation to maximize local concentration and efficacy while potentially reducing systemic side effects. Preclinical studies have demonstrated its effectiveness against antibiotic-resistant strains, including those resistant to clarithromycin and amikacin.

Other names: AJ-099 (inhaled)

Beyond the preview

Go deeper on AJ-099(I).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AJ-099(I).

Explore the full profile